Literature DB >> 10454048

Vascular-selective effect of lercanidipine and other 1,4-dihydropyridines in isolated rabbit tissues.

P Angelico1, L Guarneri, A Leonardi, R Testa.   

Abstract

The aim of this study was to characterize the in-vitro vasoselectivity of lercanidipine (in comparison with lacidipine, amlodipine, nitrendipine and felodipine) by evaluating its functional calcium antagonistic activity on rabbit vascular (aorta) and cardiac tissues (heart ventricle). Although incubation with all the compounds tested elicited a concentration-dependent relaxant effect on vascular tissue precontracted with KCl (80 mM), 50% relaxation was reached at different times for each concentration and drug tested. At 10 nM concentration 50% relaxation was reached after 210 min with lercanidipine, 278 min with amlodipine, 135 min with lacidipine, 75 min with nitrendipine and 70 min with felodipine. The onset of the effect was, therefore, similar for lercanidipine, amlodipine and lacidipine, but faster for nitrendipine and felodipine. Similarly, all the compounds tested concentration-dependently reduced the force of cardiac contraction (negative inotropic activity). In this model, the time needed to reach 50% reduction in contractile force was also concentration-dependent, and the ranking order of the speed of onset of the effect (evaluated as the ratio of the IC50 values (the concentrations inhibiting contraction by 50%) calculated after 1 and 4 h incubation) was lacidipine (3.8) > amlodipine (9.6) > felodipine (39) > lercanidipine (68) = nitrendipine (89). The vasoselectivity, expressed as the ratio of the IC50 values obtained on cardiac and vascular tissue, were (for 4 h incubation) 730, 193, 95, 6 and 3 for lercanidipine, lacidipine, amlodipine, felodipine and nitrendipine, respectively, showing that lercanidipine is the most vasoselective of the calcium-antagonists tested. The results show that lercanidipine reduces the inotropic force of the rabbit heart to a lesser extent than do other calcium antagonists, and that this drug had the best heart/vessel selectivity index among the compounds tested at all the times tested.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10454048     DOI: 10.1211/0022357991772844

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  11 in total

1.  Lercanidipine rescues hippocampus pyramidal neurons from mild ischemia-induced delayed neuronal death in SHRSP.

Authors:  Yasuko Sakurai-Yamashita; Noboru Harada; Masami Niwa
Journal:  Cell Mol Neurobiol       Date:  2011-01-23       Impact factor: 5.046

Review 2.  Lercanidipine : a review of its efficacy in the management of hypertension.

Authors:  Lynne M Bang; Therese M Chapman; Karen L Goa
Journal:  Drugs       Date:  2003       Impact factor: 9.546

3.  Molecular mechanisms of vasoselectivity of the 1,4-dihydropyridine lercanidipine.

Authors:  Susanne Wirtz; Stefan Herzig
Journal:  Br J Pharmacol       Date:  2004-05       Impact factor: 8.739

Review 4.  Lercanidipine: a review of its use in hypertension.

Authors:  K J McClellan; B Jarvis
Journal:  Drugs       Date:  2000-11       Impact factor: 11.431

Review 5.  Lercanidipine in hypertension.

Authors:  Claudio Borghi
Journal:  Vasc Health Risk Manag       Date:  2005

6.  Lercanidipine attenuates angiotensin II-induced cardiomyocyte hypertrophy by blocking calcineurin-NFAT3 and CaMKII-HDAC4 signaling.

Authors:  Yuezhang Chen; Jie Yuan; Guoliang Jiang; Jianbing Zhu; Yunzeng Zou; Qianzhou Lv
Journal:  Mol Med Rep       Date:  2017-08-10       Impact factor: 2.952

Review 7.  Discovery and Development of Calcium Channel Blockers.

Authors:  Théophile Godfraind
Journal:  Front Pharmacol       Date:  2017-05-29       Impact factor: 5.810

Review 8.  Patient adherence and the choice of antihypertensive drugs: focus on lercanidipine.

Authors:  Menno T Pruijm; Marc P Maillard; Michel Burnier
Journal:  Vasc Health Risk Manag       Date:  2008

9.  High doses of lercanidipine are better tolerated than other dihydropyridines in hypertensive patients with metabolic syndrome: results from the TOLERANCE study.

Authors:  V Barrios; C Escobar; M de la Figuera; J Honorato; J L Llisterri; J Segura; A Calderón
Journal:  Int J Clin Pract       Date:  2008-03-17       Impact factor: 2.503

Review 10.  Lercanidipine in the Management of Hypertension: An Update.

Authors:  Guido Grassi; Nicolàs R Robles; Gino Seravalle; Francesco Fici
Journal:  J Pharmacol Pharmacother       Date:  2017 Oct-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.